ADC Therapeutics restructures balance sheet with $86.6 million PIPE financing
Bitget2026/10/08 13:02ADC Therapeutics launched a financial restructuring built around an $86.6 million PIPE, expected to close Oct. 22, 2026. Royalty financing was amended to remove a $150 million change-of-control payment, easing takeover-related liabilities. Senior secured term loan was refinanced via a $70 million prepayment, cutting outstanding principal to $50 million with an August 2029 bullet maturity. Revised loan terms removed the minimum liquidity covenant, setting a trailing four-quarter U.S. ZYNLONTA sales covenant at $65 million from Q4 2026. Pro forma cash and cash equivalents were about $196 million as of Sept. 30, 2026, reflecting PIPE proceeds and the loan prepayment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY66764) on October 08, 2026, and is solely responsible for the information contained therein.
- ADC Therapeutics launched a financial restructuring built around an $86.6 million PIPE, expected to close Oct. 22, 2026.
- Royalty financing was amended to remove a $150 million change-of-control payment, easing takeover-related liabilities.
- Senior secured term loan was refinanced via a $70 million prepayment, cutting outstanding principal to $50 million with an August 2029 bullet maturity.
- Revised loan terms removed the minimum liquidity covenant, setting a trailing four-quarter U.S. ZYNLONTA sales covenant at $65 million from Q4 2026.
- Pro forma cash and cash equivalents were about $196 million as of Sept. 30, 2026, reflecting PIPE proceeds and the loan prepayment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Crypto prices
More
